Supplementary Material

List of Supplementary Material for the article

Disclaimer

This Supplementary Material has been provided by the authors as supporting information to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

eTable 1. Baseline Sociodemographic and Clinical Features of the Cohorts Used for Adherence Analyses

	STEP-2000		STEP2		STEP (combined)	
	No.	%	No.	%	No.	%
Sex (male)	738	41.7	803	43.0	1,541	42.3
Race (Caucasian)	1,637	92.4	1,649	88.2	3,286	90.3
Ethnicity (Hispanic)	75	4.2	112	6.0	187	5.1
Married	648	38.3	621	35.3	1,269	36.8
Employed	792	46.8	746	42.4	1,538	44.6
Graduated high school	1,644	97.2	1,689	96.1	3,333	96.6
Completed some college	1,409	83.3	1,427	81.2	2,836	82.2
Household income < $50k	873	56.2	963	61.1	1,836	58.7
Bipolar 1	1,227	69.3	1,144	61.2	2,371	65.1
Bipolar 2	430	24.3	536	28.7	966	26.5
Current alcohol use d.o.	182	10.3	221	11.8	403	11.1
Current drug use d.o.	116	6.5	169	9.0	285	7.8
Current anxiety d.o.	597	33.7	696	37.2	1,293	35.5
History of suicide attempt	632	36.3	666	37.4	1,298	36.9
History of psychosis	658	38.5	676	37.9	1,334	38.2
Manic episodes (5+)	1,244	70.4	1,367	73.8	2,611	72.1
Depressive episodes (5+)	1,315	75.8	1,432	78.7	2,747	77.3
Rapid cycling (ever)	1,181	66.7	1,286	68.8	2,467	67.8
Rapid cycling (past year)	780	44.0	901	48.2	1,681	46.2
	Mean	SD	Mean	SD	Mean	SD
Age at entry	40.63	12.81	39.64	12.78	40.13	12.80
Age at onset	17.43	8.83	16.93	8.67	17.18	8.76
Age at first mania	21.81	10.07	21.34	9.94	21.58	10.01
Age at first depression	18.59	9.54	17.66	9.27	18.12	9.41
Days depressed, past yr	40.34	29.84	46.17	29.59	43.25	29.85
Days anxious, past yr	29.95	32.11	40.08	34.37	34.97	33.63
Days irritable, past yr	28.39	30.10	35.09	30.34	31.73	30.40
Days elevated, past yr	18.93	21.62	19.82	20.58	19.37	21.12

Baseline sociodemographic and clinical features of the STEP2000 and STEP2 cohorts.

eFigure 1. Receiver operating characteristic curves for nonadherence risk score in model development (STEP2000; eFigure 1A) and validation (STEP2; eFigure 1B) cohorts.

eFigure 1A.

Area under ROC curve = 0.6170

eFigure 1B.

Area under ROC curve = 0.6068